Artificial intelligence for response prediction and personalisation in radiation oncology.

Artificial intelligence Normal tissue complication probability Radiotherapy Treatment response Tumour control probability

Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 10 05 2024
accepted: 14 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: aheadofprint

Résumé

Artificial intelligence (AI) systems may personalise radiotherapy by assessing complex and multifaceted patient data and predicting tumour and normal tissue responses to radiotherapy. Here we describe three distinct generations of AI systems, namely personalised radiotherapy based on pretreatment data, response-driven radiotherapy and dynamically optimised radiotherapy. Finally, we discuss the main challenges in clinical translation of AI systems for radiotherapy personalisation.

Identifiants

pubmed: 39212687
doi: 10.1007/s00066-024-02281-z
pii: 10.1007/s00066-024-02281-z
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Bernier J, Hall EJ, Giaccia A (2004) Radiation oncology: a century of achievements. Nat Rev Cancer 4:737–747. https://doi.org/10.1038/nrc1451
doi: 10.1038/nrc1451 pubmed: 15343280
Bradley JD, Hu C, Komaki RR et al (2020) Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol 38:706–714. https://doi.org/10.1200/JCO.19.01162
doi: 10.1200/JCO.19.01162 pubmed: 31841363
Baumann M, Krause M, Overgaard J et al (2016) Radiation oncology in the era of precision medicine. Nat Rev Cancer 16:234–249. https://doi.org/10.1038/nrc.2016.18
doi: 10.1038/nrc.2016.18 pubmed: 27009394
D’Souza G, Kreimer AR, Viscidi R et al (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956. https://doi.org/10.1056/NEJMoa065497
doi: 10.1056/NEJMoa065497 pubmed: 17494927
Chen M, Yang J, Liao Z et al (2020) Anatomic change over the course of treatment for non-small cell lung cancer patients and its impact on intensity-modulated radiation therapy and passive-scattering proton therapy deliveries. Radiat Oncol 15:55. https://doi.org/10.1186/s13014-020-01503-9
doi: 10.1186/s13014-020-01503-9 pubmed: 32138753 pmcid: 7059279
Stieb S, Lee A, van Dijk LV et al (2021) NTCP modeling of late effects for head and neck cancer: a systematic review. Int J Part Ther 8:95–107. https://doi.org/10.14338/20-00092
doi: 10.14338/20-00092 pubmed: 34285939 pmcid: 8270107
Dutz A, Zwanenburg A, Langendijk JA, Löck S (2022) Modelling for radiation treatment outcome. In: Troost EGC (ed) Image-guided high-precision radiotherapy. Springer, Cham, pp 285–314
doi: 10.1007/978-3-031-08601-4_13
Boersma LJ, Sattler MGA, Maduro JH et al (2022) Model-based selection for proton therapy in breast cancer: development of the national indication protocol for proton therapy and first clinical experiences. Clin Oncol 34:247–257. https://doi.org/10.1016/j.clon.2021.12.007
doi: 10.1016/j.clon.2021.12.007
Bentzen SM, Constine LS, Deasy JO et al (2010) Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 76:S3–S9. https://doi.org/10.1016/j.ijrobp.2009.09.040
doi: 10.1016/j.ijrobp.2009.09.040 pubmed: 20171515 pmcid: 3431964
Minasian LM, O’Mara A, Mitchell SA (2022) Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE® to provide two distinct and complementary perspectives. Patient Relat Outcome Meas 13:249–258. https://doi.org/10.2147/PROM.S256567
doi: 10.2147/PROM.S256567 pubmed: 36524232 pmcid: 9744864
van Dijk LV, Thor M, Steenbakkers RJHM et al (2018) Parotid gland fat related magnetic resonance image biomarkers improve prediction of late radiation-induced xerostomia. Radiother Oncol 128:459–466. https://doi.org/10.1016/j.radonc.2018.06.012
doi: 10.1016/j.radonc.2018.06.012 pubmed: 29958772 pmcid: 6625348
Kuhn M, Johnson K (2018) Applied predictive modeling. Springer, New York
Zaider M, Hanin L (2011) Tumor control probability in radiation treatment. Med Phys 38:574–583. https://doi.org/10.1118/1.3521406
doi: 10.1118/1.3521406 pubmed: 21452694
International Commission on Radiation Units and Measurements (1999) ICRU report 62, prescribing, recording and reporting photon beam therapy (supplement to ICRU 50). ICRU
International Commission on Radiation Units and Measurements (2007) ICRU report 78, prescribing, recording, and reporting proton-beam therapy. ICRU
International Commission on Radiation Units and Measurements (2010) ICRU report 83 prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU
Brock KK (2019) Adaptive radiotherapy: moving into the future. Semin Radiat Oncol 29:181–184. https://doi.org/10.1016/j.semradonc.2019.02.011
doi: 10.1016/j.semradonc.2019.02.011 pubmed: 31027635 pmcid: 7219982
Wolterink JM, Leiner T, Viergever MA, Isgum I (2017) Generative adversarial networks for noise reduction in low-dose CT. IEEE Trans Med Imaging 36:2536–2545. https://doi.org/10.1109/TMI.2017.2708987
doi: 10.1109/TMI.2017.2708987 pubmed: 28574346
Xing Y, Zhang Y, Nguyen D et al (2020) Boosting radiotherapy dose calculation accuracy with deep learning. J Appl Clin Med Phys 21:149–159. https://doi.org/10.1002/acm2.12937
doi: 10.1002/acm2.12937 pubmed: 32559018 pmcid: 7484829
Mylonas A, Booth J, Nguyen DT (2021) A review of artificial intelligence applications for motion tracking in radiotherapy. J Med Imaging Radiat Oncol 65:596–611. https://doi.org/10.1111/1754-9485.13285
doi: 10.1111/1754-9485.13285 pubmed: 34288501
Leger S, Zwanenburg A, Pilz K et al (2019) CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. Radiother Oncol 130:10–17. https://doi.org/10.1016/j.radonc.2018.07.020
doi: 10.1016/j.radonc.2018.07.020 pubmed: 30087056
Starke S, Zwanenburg A, Leger K et al (2023) Longitudinal and multimodal radiomics models for head and neck cancer outcome prediction. Cancers 15:673. https://doi.org/10.3390/cancers15030673
doi: 10.3390/cancers15030673 pubmed: 36765628 pmcid: 9913206
Ajdari A, Niyazi M, Nicolay NH et al (2019) Towards optimal stopping in radiation therapy. Radiother Oncol 134:96–100. https://doi.org/10.1016/j.radonc.2019.01.010
doi: 10.1016/j.radonc.2019.01.010 pubmed: 31005230
Enriquez-Navas PM, Wojtkowiak JW, Gatenby RA (2015) Application of evolutionary principles to cancer therapy. Cancer Res 75:4675–4680. https://doi.org/10.1158/0008-5472.CAN-15-1337
doi: 10.1158/0008-5472.CAN-15-1337 pubmed: 26527288 pmcid: 4693617
Gatenby RA, Brown JS (2020) Integrating evolutionary dynamics into cancer therapy. Nat Rev Clin Oncol 17:675–686. https://doi.org/10.1038/s41571-020-0411-1
doi: 10.1038/s41571-020-0411-1 pubmed: 32699310
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026 pubmed: 19097774
Kidd AC, Anderson O, Cowell GW et al (2022) Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. Thorax 77:1251–1259. https://doi.org/10.1136/thoraxjnl-2021-217808
doi: 10.1136/thoraxjnl-2021-217808 pubmed: 35110367
Joskowicz L, Szeskin A, Rochman S et al (2023) Follow-up of liver metastases: a comparison of deep learning and RECIST 1.1. Eur Radiol 33:9320–9327. https://doi.org/10.1007/s00330-023-09926-0
doi: 10.1007/s00330-023-09926-0 pubmed: 37480549
Gong A, Daly M, Melendez-Corres G et al (2023) Toward automating RECIST 1.1: Improving AI new lesion detection with longitudinal image data. J Clin Orthod 41:e13545–e13545. https://doi.org/10.1200/JCO.2023.41.16_suppl.e13545
doi: 10.1200/JCO.2023.41.16_suppl.e13545
Thust SC, van den Bent MJ, Smits M (2018) Pseudoprogression of brain tumors. J Magn Reson Imaging 48:571–589. https://doi.org/10.1002/jmri.26171
doi: 10.1002/jmri.26171 pubmed: 29734497 pmcid: 6175399
Park HJ, Kim KW, Pyo J et al (2020) Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology 297:87–96. https://doi.org/10.1148/radiol.2020200443
doi: 10.1148/radiol.2020200443 pubmed: 32749204
Akbari H, Rathore S, Bakas S et al (2020) Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. Cancer 126:2625–2636. https://doi.org/10.1002/cncr.32790
doi: 10.1002/cncr.32790 pubmed: 32129893
Kamel Boulos MN, Zhang P (2021) Digital twins: from personalised medicine to precision public health. J Pers Med. https://doi.org/10.3390/jpm11080745
doi: 10.3390/jpm11080745 pubmed: 34442389 pmcid: 8401029
Price JM, Prabhakaran A, West CML (2023) Predicting tumour radiosensitivity to deliver precision radiotherapy. Nat Rev Clin Oncol 20:83–98. https://doi.org/10.1038/s41571-022-00709-y
doi: 10.1038/s41571-022-00709-y pubmed: 36477705
Gabryś HS, Buettner F, Sterzing F et al (2018) Design and selection of machine learning methods using radiomics and dosiomics for normal tissue complication probability modeling of xerostomia. Front Oncol 8:35. https://doi.org/10.3389/fonc.2018.00035
doi: 10.3389/fonc.2018.00035 pubmed: 29556480 pmcid: 5844945
Jelonek K, Pietrowska M, Widlak P (2017) Systemic effects of ionizing radiation at the proteome and metabolome levels in the blood of cancer patients treated with radiotherapy: the influence of inflammation and radiation toxicity. Int J Radiat Biol 93:683–696. https://doi.org/10.1080/09553002.2017.1304590
doi: 10.1080/09553002.2017.1304590 pubmed: 28281355
Neri E, Del Re M, Paiar F et al (2018) Radiomics and liquid biopsy in oncology: the holons of systems medicine. Insights Imaging 9:915–924. https://doi.org/10.1007/s13244-018-0657-7
doi: 10.1007/s13244-018-0657-7 pubmed: 30430428 pmcid: 6269342
McLaren DB, Aitman TJ (2023) Redefining precision radiotherapy through liquid biopsy. Br J Cancer 129:900–903. https://doi.org/10.1038/s41416-023-02398-5
doi: 10.1038/s41416-023-02398-5 pubmed: 37598284 pmcid: 10491827
Kelly CJ, Karthikesalingam A, Suleyman M et al (2019) Key challenges for delivering clinical impact with artificial intelligence. BMC Med 17:195. https://doi.org/10.1186/s12916-019-1426-2
doi: 10.1186/s12916-019-1426-2 pubmed: 31665002 pmcid: 6821018
O’Connor JPB, Robinson SP, Waterton JC (2019) Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. Br J Radiol 92:20180642. https://doi.org/10.1259/bjr.20180642
doi: 10.1259/bjr.20180642 pubmed: 30272998
Busk M, Overgaard J, Horsman MR (2020) Imaging of tumor hypoxia for radiotherapy: current status and future directions. Semin Nucl Med 50:562–583. https://doi.org/10.1053/j.semnuclmed.2020.05.003
doi: 10.1053/j.semnuclmed.2020.05.003 pubmed: 33059825
McCarthy CE, White JM, Viola NT, Gibson HM (2020) In vivo imaging technologies to monitor the immune system. Front Immunol 11:1067. https://doi.org/10.3389/fimmu.2020.01067
doi: 10.3389/fimmu.2020.01067 pubmed: 32582173 pmcid: 7280489
Jackson A, Marks LB, Bentzen SM et al (2010) The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 76:S155–60. https://doi.org/10.1016/j.ijrobp.2009.08.074
doi: 10.1016/j.ijrobp.2009.08.074 pubmed: 20171512 pmcid: 2854159
Mercer TR, Xu J, Mason CE et al (2021) The sequencing quality control 2 study: establishing community standards for sequencing in precision medicine. Genome Biol 22:306. https://doi.org/10.1186/s13059-021-02528-3
doi: 10.1186/s13059-021-02528-3 pubmed: 34749795 pmcid: 8574019
Zwanenburg A (2023) Standardisation and harmonisation efforts in quantitative imaging. Eur Radiol 33:8842–8843. https://doi.org/10.1007/s00330-023-09921-5
doi: 10.1007/s00330-023-09921-5 pubmed: 37466706
Rieke N, Hancox J, Li W et al (2020) The future of digital health with federated learning. NPJ Digit Med 3:119. https://doi.org/10.1038/s41746-020-00323-1
doi: 10.1038/s41746-020-00323-1 pubmed: 33015372 pmcid: 7490367
Price G, Peek N, Eleftheriou I et al (2024) An overview of real-world data infrastructure for cancer research. Clin Oncol. https://doi.org/10.1016/j.clon.2024.03.011
doi: 10.1016/j.clon.2024.03.011
Mali SA, Ibrahim A, Woodruff HC et al (2021) Making radiomics more reproducible across scanner and imaging protocol variations: a review of harmonization methods. J Pers Med 11:842. https://doi.org/10.3390/jpm11090842
doi: 10.3390/jpm11090842 pubmed: 34575619 pmcid: 8472571
Spigel DR, Faivre-Finn C, Gray JE et al (2022) Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 40:1301–1311. https://doi.org/10.1200/JCO.21.01308
doi: 10.1200/JCO.21.01308 pubmed: 35108059 pmcid: 9015199
Grégoire V, Guckenberger M, Haustermans K et al (2020) Image guidance in radiation therapy for better cure of cancer. Mol Oncol 14:1470–1491. https://doi.org/10.1002/1878-0261.12751
doi: 10.1002/1878-0261.12751 pubmed: 32536001 pmcid: 7332209
Surti S, Karp JS (2020) Update on latest advances in time-of-flight PET. Phys Med 80:251–258. https://doi.org/10.1016/j.ejmp.2020.10.031
doi: 10.1016/j.ejmp.2020.10.031 pubmed: 33212421 pmcid: 7749844
Marx V (2023) Method of the year: long-read sequencing. Nat Methods 20:6–11. https://doi.org/10.1038/s41592-022-01730-w
doi: 10.1038/s41592-022-01730-w pubmed: 36635542
Sahiner B, Chen W, Samala RK, Petrick N (2023) Data drift in medical machine learning: implications and potential remedies. Br J Radiol 96:20220878. https://doi.org/10.1259/bjr.20220878
doi: 10.1259/bjr.20220878 pubmed: 36971405
Grote T (2022) Randomised controlled trials in medical AI: ethical considerations. J Med Ethics 48:899–906. https://doi.org/10.1136/medethics-2020-107166
doi: 10.1136/medethics-2020-107166 pubmed: 33990429
Kane PB, Kimmelman J (2021) Is preclinical research in cancer biology reproducible enough? Elife. https://doi.org/10.7554/eLife.67527
doi: 10.7554/eLife.67527 pubmed: 34874006 pmcid: 8651283
Shahzadi I, Zwanenburg A, Lattermann A et al (2022) Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models. Sci Rep 12:1–15. https://doi.org/10.1038/s41598-022-13967-8
doi: 10.1038/s41598-022-13967-8
Friedman B, Nissenbaum H (1996) Bias in computer systems. ACM Trans Inf Syst Secur 14:330–347. https://doi.org/10.1145/230538.230561
doi: 10.1145/230538.230561
Hutchinson B, Mitchell M (2019) 50 years of test (un)fairness: lessons for machine learning. In: Proceedings of the conference on fairness, accountability, and transparency. Association for Computing Machinery, New York, NY, USA, pp 49–58
doi: 10.1145/3287560.3287600
Abdel-Wahab M, Gondhowiardjo SS, Rosa AA et al (2021) Global radiotherapy: current status and future directions-white paper. JCO Glob Oncol 7:827–842. https://doi.org/10.1200/GO.21.00029
doi: 10.1200/GO.21.00029 pubmed: 34101482
Deb S, Pendharkar AV, Schoen MK et al (2017) The effect of socioeconomic status on gross total resection, radiation therapy and overall survival in patients with gliomas. J Neurooncol 132:447–453. https://doi.org/10.1007/s11060-017-2391-2
doi: 10.1007/s11060-017-2391-2 pubmed: 28258423
Laan JJ, van Lonkhuijzen LRCW, van Os RM et al (2017) Socioeconomic status as an independent risk factor for severe late bowel toxicity after primary radiotherapy for cervical cancer. Gynecol Oncol 147:684–689. https://doi.org/10.1016/j.ygyno.2017.10.013
doi: 10.1016/j.ygyno.2017.10.013 pubmed: 29074259
Stahl BC, Antoniou J, Bhalla N et al (2023) A systematic review of artificial intelligence impact assessments. Artif Intell Rev. https://doi.org/10.1007/s10462-023-10420-8
doi: 10.1007/s10462-023-10420-8 pubmed: 37362899 pmcid: 10037374
van de Sande D, Chung EFF, Oosterhoff J et al (2024) To warrant clinical adoption AI models require a multi-faceted implementation evaluation. NPJ Digit Med 7:58. https://doi.org/10.1038/s41746-024-01064-1
doi: 10.1038/s41746-024-01064-1 pubmed: 38448743 pmcid: 10918103
Claessens M, Oria CS, Brouwer CL et al (2022) Quality assurance for AI-based applications in radiation therapy. Semin Radiat Oncol 32:421–431. https://doi.org/10.1016/j.semradonc.2022.06.011
doi: 10.1016/j.semradonc.2022.06.011 pubmed: 36202444
Vandewinckele L, Claessens M, Dinkla A et al (2020) Overview of artificial intelligence-based applications in radiotherapy: recommendations for implementation and quality assurance. Radiother Oncol 153:55–66. https://doi.org/10.1016/j.radonc.2020.09.008
doi: 10.1016/j.radonc.2020.09.008 pubmed: 32920005
Sutton RT, Pincock D, Baumgart DC et al (2020) An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med 3:17. https://doi.org/10.1038/s41746-020-0221-y
doi: 10.1038/s41746-020-0221-y pubmed: 32047862 pmcid: 7005290

Auteurs

Alex Zwanenburg (A)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstr. 74, PF 41, 01307, Dresden, Germany. alexander.zwanenburg@nct-dresden.de.
National Center for Tumor Diseases Dresden (NCT/UCC), Germany:, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. alexander.zwanenburg@nct-dresden.de.
German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany. alexander.zwanenburg@nct-dresden.de.

Gareth Price (G)

Division of Cancer Sciences, University of Manchester, Manchester, UK.
The Christie NHS Foundation Trust, Manchester, UK.

Steffen Löck (S)

OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Helmholtz-Zentrum Dresden-Rossendorf, Fetscherstr. 74, PF 41, 01307, Dresden, Germany.
Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.

Classifications MeSH